352 related articles for article (PubMed ID: 22048117)
1. Buruli ulcer.
Einarsdottir T; Huygen K
Hum Vaccin; 2011 Nov; 7(11):1198-203. PubMed ID: 22048117
[TBL] [Abstract][Full Text] [Related]
2. Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.
Hart BE; Hale LP; Lee S
PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004046. PubMed ID: 26393347
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer.
Bolz M; Bénard A; Dreyer AM; Kerber S; Vettiger A; Oehlmann W; Singh M; Duthie MS; Pluschke G
PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004431. PubMed ID: 26849213
[TBL] [Abstract][Full Text] [Related]
4. Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection.
Walsh DS; Portaels F; Meyers WM
Dermatol Clin; 2011 Jan; 29(1):1-8. PubMed ID: 21095521
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of a dewaxed whole-cell vaccine against Mycobacterium ulcerans infection in mice.
Watanabe M; Nakamura H; Nabekura R; Shinoda N; Suzuki E; Saito H
Vaccine; 2015 May; 33(19):2232-2239. PubMed ID: 25825332
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans infected mice.
Roupie V; Pidot SJ; Einarsdottir T; Van Den Poel C; Jurion F; Stinear TP; Huygen K
PLoS Negl Trop Dis; 2014; 8(1):e2604. PubMed ID: 24392169
[TBL] [Abstract][Full Text] [Related]
7. Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer.
Hall B; Simmonds R
Biochem Soc Trans; 2014 Feb; 42(1):177-83. PubMed ID: 24450648
[TBL] [Abstract][Full Text] [Related]
8. Buruli ulcer (Mycobacterium ulcerans infection).
Walsh DS; Portaels F; Meyers WM
Trans R Soc Trop Med Hyg; 2008 Oct; 102(10):969-78. PubMed ID: 18657836
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy.
Hart BE; Lee S
PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005229. PubMed ID: 27941982
[TBL] [Abstract][Full Text] [Related]
10. Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer.
Silva MT; Portaels F; Pedrosa J
Lancet Infect Dis; 2009 Nov; 9(11):699-710. PubMed ID: 19850228
[TBL] [Abstract][Full Text] [Related]
11. Skin-specific antibodies neutralizing mycolactone toxin during the spontaneous healing of
Foulon M; Pouchin A; Manry J; Khater F; Robbe-Saule M; Durand A; Esnault L; Delneste Y; Jeannin P; Saint-André JP; Croué A; Altare F; Abel L; Alcaïs A; Marion E
Sci Adv; 2020 Feb; 6(9):eaax7781. PubMed ID: 32133396
[TBL] [Abstract][Full Text] [Related]
12. Use of Recombinant Virus Replicon Particles for Vaccination against Mycobacterium ulcerans Disease.
Bolz M; Kerber S; Zimmer G; Pluschke G
PLoS Negl Trop Dis; 2015; 9(8):e0004011. PubMed ID: 26275222
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in leprosy and Buruli ulcer (Mycobacterium ulcerans infection).
Walsh DS; Portaels F; Meyers WM
Curr Opin Infect Dis; 2010 Oct; 23(5):445-55. PubMed ID: 20581668
[TBL] [Abstract][Full Text] [Related]
14. The genome, evolution and diversity of Mycobacterium ulcerans.
Röltgen K; Stinear TP; Pluschke G
Infect Genet Evol; 2012 Apr; 12(3):522-9. PubMed ID: 22306192
[TBL] [Abstract][Full Text] [Related]
15. On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer.
Doig KD; Holt KE; Fyfe JA; Lavender CJ; Eddyani M; Portaels F; Yeboah-Manu D; Pluschke G; Seemann T; Stinear TP
BMC Genomics; 2012 Jun; 13():258. PubMed ID: 22712622
[TBL] [Abstract][Full Text] [Related]
16. Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.
Fraga AG; Martins TG; Torrado E; Huygen K; Portaels F; Silva MT; Castro AG; Pedrosa J
PLoS One; 2012; 7(3):e33406. PubMed ID: 22413022
[TBL] [Abstract][Full Text] [Related]
17. Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.
Demangel C; Stinear TP; Cole ST
Nat Rev Microbiol; 2009 Jan; 7(1):50-60. PubMed ID: 19079352
[TBL] [Abstract][Full Text] [Related]
18. Structural basis and designing of peptide vaccine using PE-PGRS family protein of Mycobacterium ulcerans-An integrated vaccinomics approach.
Nain Z; Karim MM; Sen MK; Adhikari UK
Mol Immunol; 2020 Apr; 120():146-163. PubMed ID: 32126449
[TBL] [Abstract][Full Text] [Related]
19. Buruli ulcer and mycolactone-producing mycobacteria.
Nakanaga K; Yotsu RR; Hoshino Y; Suzuki K; Makino M; Ishii N
Jpn J Infect Dis; 2013; 66(2):83-8. PubMed ID: 23514902
[TBL] [Abstract][Full Text] [Related]
20. Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs.
Hong H; Coutanceau E; Leclerc M; Caleechurn L; Leadlay PF; Demangel C
PLoS Negl Trop Dis; 2008; 2(10):e325. PubMed ID: 18941518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
